Sign In
Buy ASLN
$0.600
+0 (+0%)
At Close: Oct 17, 2024
ASLAN Pharmaceuticals to Present Data on ASLAN004 at Society for Investigative Dermatology
05:22am, Wednesday, 05'th May 2021
- ASLAN will give a poster presentation of new data from its Single Ascending Dose (SAD) study of ASLAN004, during the virtual event on 6 May, 2021
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
07:51am, Thursday, 22'nd Apr 2021
Next data readout for ASLAN004 in the treatment of patients with moderate to severe atopic dermatitis anticipated in the third quarter of 2021 Next data readout for ASLAN004 in the treatment of patien
ASLAN Pharmaceuticals Announces Pricing of Public Offering of American Depositary Shares
12:42am, Wednesday, 03'rd Mar 2021
SINGAPORE, March 03, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the live
ASLAN Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares
04:01pm, Monday, 01'st Mar 2021
SINGAPORE, March 01, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the live
ASLN Stock: Why Aslan Pharmaceuticals Is Up 20% Today
02:12pm, Monday, 01'st Mar 2021
Investors in ASLN stock seem to like the company's initial clinical test results, as well as the company's overall market position. The post ASLN Stock: Why Aslan Pharmaceuticals Is Up 20% Today appea
ASLN Stock Price Increases Over 70% Pre-Market: Why It Happened
07:30am, Monday, 01'st Mar 2021
The stock price of Aslan Pharmaceuticals Ltd (NASDAQ: ASLN) has increased by over 70% pre-market. This is why it happened.
ASLAN Pharmaceuticals Announces Positive Interim Data From the Multiple Ascending Dose Study of ASLAN004 in Atopic Dermatitis
06:00am, Monday, 01'st Mar 2021
- 74% average reduction in EASI from baseline at therapeutic doses after 8 weeks. 89% of patients achieved EASI-50 and 56% achieved EASI-90
ASLAN Pharmaceuticals Announces $18 Million Private Placement
06:30am, Thursday, 25'th Feb 2021
SINGAPORE, Feb. 25, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives
ASLAN Pharmaceuticals Appoints Dr Neil Graham as Independent Director
07:00am, Thursday, 18'th Feb 2021
SINGAPORE, Feb. 18, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the l
— New research shows ASLAN003 to have the lowest potential for hepatotoxicity of the compounds tested despite being one of the most potent DHODH inhibitors
ASLAN Pharmaceuticals Opens Expansion Cohort in ASLAN004 Atopic Dermatitis Clinical Trial
05:34am, Monday, 11'th Jan 2021
- ASLAN has completed recruitment of patients into the third, highest dose cohort of ASLAN004 in AD patients. ASLAN004 was found to be well tolerated at all dose levels
ASLAN Pharmaceuticals Ltd. (ASLN) Moves to Buy: Rationale Behind the Upgrade
12:47pm, Friday, 25'th Dec 2020
ASLAN Pharmaceuticals Ltd. (ASLN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ASLAN Pharmaceuticals to Present at Upcoming Piper Sandler Investor Conference
07:22am, Thursday, 19'th Nov 2020
SINGAPORE, Nov. 19, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives
ASLAN Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
07:00am, Monday, 09'th Nov 2020
SINGAPORE, Nov. 09, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives
ASLAN Pharmaceuticals to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference 2020
07:00am, Friday, 07'th Aug 2020
SINGAPORE, Aug. 07, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments
